Based on our expertise, we offer contract research options for the development of rapid lateral flow tests for Point-of-Care diagnostics, as well as the development of new immunological therapy options for various diseases.
maintect GmbH is a biotech company, based in Mainz (Germany), dedicated to the development of immunochromatographic rapid test devices (lateral flow assays) for the early detection of disease and antibody-based treatments. Our more immediate research and development goals include the POC diagnosis of eye diseases, including AMD, the development of minimally invasive sampling systems, and taking our AMD antibody treatment project to preclinical trials. maintect GmbH works in close collaboration with the Experimental and Translational Ophthalmology at the University of Mainz (Experimentelle and Translational Ophthalmologie, Augenklinik und Poliklinik, Universitätsmedizin Mainz).
AMD is a degenerative disease of the retina leading to a loss of visual function. It is one of the principal causes of visual impairment in the world and the leading cause of blindness in developed countries.
Estimation: number of people with AMD in 2020 is 196 million, increasing to 288 million in 2040.
Furthermore, we plan to bring forward the development of a new therapeutic approach particularly for anti-VEGF-non-responders, but also as a general new therapeutic option for wet AMD and dry AMD. In vitro and in vivo tests with our molecule of choice have generated very promising results and target a completely new therapeutic pathway.
Besides working on our own research projects, maintect GmbH provides a specialized service platform for the development of your lateral flow assays (LFA) based on different body fluids, as well as contract work for immune therapy based on our existing expertise in the area of antibody drug development.